Full Text View
Tabular View
No Study Results Posted
Related Studies
Impact of Oral Contraceptives on GABA and Neurosteroids
This study has been terminated.
( Funding withdrawn from study sponsor. )

First Received on April 7, 2008.   Last Updated on August 24, 2009   History of Changes
Sponsor: Yale University
Information provided by: Yale University
ClinicalTrials.gov Identifier: NCT00656318
  Purpose

Thus, the proposed study has the following Specific Aims and Hypotheses:

  1. To determine in menstruating women ages 18-45 whether an OCP containing ethinyl estradiol (EE) and the progestin ethinydiol diacetate (ED) increases cortical GABA concentrations as measured using proton magnetic resonance spectroscopy (1H-MRS) above that of an OCP containing EE and the progestin norethindrone (NOR).
  2. To determine the relationship between changes in occipital GABA concentrations with acute OCP administration and negative affect with chronic OCP administration over two menstrual cycles.

Condition Intervention
Healthy
 Other: oral contraceptive pill (OCP; OCPs)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Oral Contraceptives on GABA and Neurosteroids

Resource links provided by NLM:

Drug Information available for: Modicon Ethinyl estradiol mixture with norethindrone Norinyl
U.S. FDA Resources

Further study details as provided by Yale University:

Primary Outcome Measures:
  • The purpose of this study is to investigate the effect of oral contraceptive pills (OCPs) on cortical GABA concentrations as measured by proton magnetic resonance spectroscopy (1H-MRS) in non-depressed, healthy menstruating women. [ Time Frame: Outcomes will be measured at several points during each participants menstrual cycle. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine the impact of OCP use on plasma and cerebral spinal fluid (CSF) levels of estradiol (E2) and progesterone, as well as neurosteroids such as pregnenolone, allopregnanolone, pregnanolone and 5 alpha-dihydroprogesterone (5α-DHP). [ Time Frame: Outcome will be assessed at several time points for each participant. ] [ Designated as safety issue: No ]

Enrollment: 6
Study Start Date: August 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 (Zovia)
Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
 Other: oral contraceptive pill (OCP; OCPs)
Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
Other Names:
  • Zovia 1/35
  • Necon
Group 2 (Necon)
Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
 Other: oral contraceptive pill (OCP; OCPs)
Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
Other Names:
  • Zovia 1/35
  • Necon

Detailed Description:

Approximately 11.6 million women in the United States use oral contraceptives (OCs) each year. The vast majority of OCs combine both estrogen and a type of progestin, or progesterone-like substance into one pill which is taken daily. Depression or a negative change in mood, apparently resulting from the use of OCs, is thought to be one of the main reasons women miss pills or stop taking their oral contraceptive pills (OCPs) altogether. Clinical observation that some women develop depression when taking progestin only OCs or when adding progestins to menopausal estrogen therapy has led to the speculation that the progestin is the likely culprit of these negative mood changes in women using combined OCPs.

The current study is designed to investigate the role of progestins in the development of mood symptoms in OCP users. Women participating in this study will receive one of two different OCPs for three months. Their mood while taking the OCPs will be compared to their mood prior to using OCPs. In addition, each woman will undergo a brain imaging study after the first dose of their OCP to determine whether acute changes in brain chemistry in response to the OCP predicts change in mood with OCP use. By choosing OCPs with the same estrogen product but 2 different types of progestins we hope to determine whether one type of progestin is more likely to result in negative mood.

Determining factors that contribute to the emergence of depression with OC use is the first step in developing newer oral contraceptives that do not have this health outcome and will ultimately improve compliance with OCP use. Reducing side effects of OCPs is likely to improve compliance and thus decrease the prevalence of unwanted pregnancy.

  Eligibility

Ages Eligible for Study:   18 Years to 42 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Women between the ages of 18 and 42 with regular menstrual cycles of 28-32 days will be invited to participate in a brain imaging study examining the effects of two different oral contraceptives on cortical GABA levels.

Criteria

Inclusion Criteria:

  • Aged 18 - 42 years old and able to give voluntary written informed consent.
  • Willing to complete a daily log of mood symptoms for 3 consecutive menstrual cycles.
  • Be off of OCPs for at least 3 menstrual periods prior to beginning the study and be willing to go on OCPs for the study.
  • Provide documentation of a normal PAP smear, pelvic and breast examination within the previous 12 months prior to enrollment.
  • Have regular menstrual cycles 28 to 32 days in length prior to enrollment. The screening cycle must be ovulatory as confirmed by plasma progesterone levels of >3 ng/ml during the luteal phase.
  • Negative pregnancy blood test at admission; negative urine pregnancy test on the MRS testing day.

Exclusion Criteria:

  • Presence of any DSM-IV Axis I disorder, excepting possible mild to moderate PMS/PMDD, within the previous 12 months.
  • Lifetime history of any psychotic disorder, including bipolar disorder.
  • Meeting DSM-IV criteria for psychoactive substance (including nicotine) abuse/dependence within the preceding 6 months.
  • A history of serious medical or neurological illness, including (but not limited to) major cardiovascular disease, hypertension (SBP > 140 mm Hg and DBP > 90 mm Hg), intracranial mass lesions, seizure disorder, severe hepatic or renal disease, unstable endocrine or metabolic disease, unstable hematologic disease, gynecologic cancer and gallbladder disease, venous thromboembolism, and stroke.
  • Diabetes if present with one other cardiovascular risk factor such as hypercholesterolemia or hypertension.
  • Hypercholesterolemia if LDL > 160 mg/dl.
  • Use of any psychotropic medication within the previous month.
  • Alcohol consumption greater than 7 drinks/week.
  • Current pregnancy or planning to become pregnant during the course of the study.
  • Metallic implants.
  • History of or suspected claustrophobias.
  • Migraine headaches if > 35 yo.
  • Weigh >300 lbs (the 4T magnet has a weight limit <300 lbs)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00656318

Locations
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: C. Neill Epperson, M.D. Yale University School of Medicine Department of Psychiatry
  More Information

No publications provided

Responsible Party: C. Neill Epperson, M.D., Yale University School of Medicine Department of Psychiatry
ClinicalTrials.gov Identifier: NCT00656318     History of Changes
Other Study ID Numbers: 0701002178
Study First Received: April 7, 2008
Last Updated: August 24, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
women
menses
oral contraceptives
Healthy menstruating females

Additional relevant MeSH terms:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Neurotransmitter Agents
Reproductive Control Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptive Agents, Female
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 09, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services